Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia

May 18, 2017 updated by: Eastern Cooperative Oncology Group

Analysis of Serum 2-Hydroxyglutarate (2HG) Levels, IDH Mutations and Clinical Outcome in Acute Myeloid Leukemia (AML)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and lean more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in blood samples from patients with acute myeloid leukemia.

Study Overview

Status

Completed

Conditions

Leukemia

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary

To determine if serum 2-hydroxyglutarate (2HG) is only detected in acute myeloid leukemia (AML) patients with isocitrate dehydrogenase (IDH) mutations.

Secondary

To determine if the level of serum 2HG impacts leukemia-free survival (LFS).
To determine if the level of serum 2HG impacts overall survival (OS).
To determine if serum 2HG is undetectable at the time of documented clinical remission (CR) in IDH-mutated patients.

OUTLINE: Archived serum samples are analyzed for 2-hydroxyglutarate expression by reverse-phase liquid chromatography coupled to mass spectrometry. Results are then compared with presence or absence of an IDH mutation, patients' clinical outcome, as well as age, sex, white blood cell count at diagnosis, platelet count, bone marrow blast percentage at diagnosis, circulating (serum) percentage at diagnosis, cytogenetic risk group, presence of FLT3, NPMN1, and/or TET2 mutations, specific IDH mutation, and randomization treatment group allocation.

Study Type

Observational

Enrollment (Actual)

220

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 60 years (ADULT, CHILD)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Samples from patients enrolled on E1900 from whom samples were submitted for research

Description

DISEASE CHARACTERISTICS:

Morphologically confirmed acute myeloid leukemia (AML)
- Newly diagnosed with AML
- Serum samples from patients enrolled on the ECOG-1900 clinical trial between 2002 and 2008
- Patients with or without isocitrate dehydrogenase (IDH) mutations

PATIENT CHARACTERISTICS:

Not specified

PRIOR CONCURRENT THERAPY:

Received 2 different doses of standard induction chemotherapy on ECOG-1900

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Absence of serum 2HG in all samples without an IDH mutation Time Frame: 1 day	1 day

Secondary Outcome Measures

Outcome Measure	Time Frame
Relationship between 2HG level and survival outcomes Time Frame: 1 day	1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eastern Cooperative Oncology Group

Collaborators

National Cancer Institute (NCI)

Investigators

Principal Investigator: Courtney DiNardo, MD, Abramson Cancer Center of the University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 3, 2012

Primary Completion (ACTUAL)

February 3, 2012

Study Completion (ACTUAL)